Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03512171 · ClinicalTrials.gov registry record · Phase 1
Decision Making Study in Young and Middle-Aged Adults: Part II
A Phase 1 study, sponsored by Vanderbilt University.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT03512171: Completed Phase 1 study, sponsored by Vanderbilt University.
NCT03512171 is a Phase 1 study that has completed, run by Vanderbilt University. The registered enrollment target is 65 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03512171, a Phase 1 study, has completed, sponsored by Vanderbilt University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
Financial decisions are made during pre-retirement age that can influence financial well-being for the rest of an individual's life. This proposal aims to construct a more comprehensive model of the specific psychological and neural mechanisms that support financial decisions in young adulthood and late middle age. In Part 1 of this study (covered in Institutional Review Board (IRB) # 141812), middle-age and young adults complete basic cognitive, motivational, and decision making tasks and are studied with functional magnetic resonance imaging (fMRI) to determine the relation between neural circuit activation and individual and age-related differences in decision making. In part II of the study, aspects of dopamine functioning are studied using positron emission tomography (PET) scanning to determine whether individual differences in dopamine functions are related to the decision-making and fMRI measures collected in Part 1 of the study. Dopamine measures include baseline D2 receptor availability, amphetamine induced dopamine release and dopamine transporter (DAT) levels, which provides a more comprehensive evaluation of dopamine functions than in prior studies linking individual differences in dopamine to behavioral, cognitive or decision-making traits.
Primary Outcome
D2 receptor availability is measured using positron emission tomography (PET) and the D2/D3 receptor radioligand \[18F\] fallypride. Contrast between receptor availability after amphetamine versus placebo forms the primary measure of dopamine release induced by amphetamine.
Interventions
- DRUG Placebo
- DRUG Dextroamphetamine
- DIAGNOSTIC_TEST [18F]Fallypride
- DIAGNOSTIC_TEST [18F]-FE-PE2I
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2016-03-31 |
| Est. Completion | 2018-05-15 |
| Phase | Phase 1 |
What the finished NCT03512171 record still lists
NCT03512171 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03512171 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03512171 about?
NCT03512171 is a clinical study titled "Decision Making Study in Young and Middle-Aged Adults: Part II". Financial decisions are made during pre-retirement age that can influence financial well-being for the rest of an individual's life. This proposal aims to construct a more comprehensive model of the specific psychological and neural mechanisms that support financial decisions in young adulthood and ...
What is the current status of trial NCT03512171?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2016-03-31. Estimated completion is 2018-05-15.
What interventions are being tested in trial NCT03512171?
The interventions under investigation include: Placebo (DRUG), Dextroamphetamine (DRUG), [18F]Fallypride (DIAGNOSTIC_TEST), [18F]-FE-PE2I (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03512171?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03512171's enrollment target sits among peer trials
65 798th of 2000 higher than 1,193 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI